Silkenstedt E, Salles G, Campo E, Dreyling M. B-cell non-Hodgkin lymphomas. Lancet. 2024;403(10438):1791–807.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramirez-Gamero A, Martinez-Cordero H, Beltran BE, Florindez J, Malpica L, Castillo JJ. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(8):1586–94.

Article  CAS  PubMed  Google Scholar 

Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024;143(16):1565–75.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024;143(6):496–506.

Article  CAS  PubMed  Google Scholar 

Woyach JA, Stephens DM, Flinn IW, Bhat SA, Savage RE, Chai F, et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Cancer Discov. 2024;14(1):66–75.

Article  CAS  PubMed  Google Scholar 

Wang XW, Yang SG, Hu MW, Wang RY, Zhang C, Kosanam AR, et al. Histone methyltransferase Ezh2 coordinates mammalian axon regeneration via regulation of key regenerative pathways. J Clin Invest. 2024;134(3).

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat Commun. 2024;15(1):6779.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maruyama D, Jacobsen E, Porcu P, Allen P, Ishitsuka K, Kusumoto S, et al. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study. Lancet Oncol. 2024;25(12):1589–601.

Article  CAS  PubMed  Google Scholar 

Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018;19(5):649–59.

Article  CAS  PubMed  Google Scholar 

Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dinh E, Rival T, Carrier A, Asfogo N, Corti O, Melon C, et al. TP53INP1 exerts neuroprotection under ageing and Parkinson’s disease-related stress condition. Cell Death Dis. 2021;12(5):460.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saadi H, Seillier M, Carrier A. The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. Biochimie. 2015;118:44–50.

Article  CAS  PubMed  Google Scholar 

Li G, Yan X. Long non-coding RNA GAS5 promotes cisplatin-chemosensitivity of osteosarcoma cells via microRNA-26b-5p/TP53INP1 axis. J Orthop Surg Res. 2023;18(1):890.

Article  PubMed  PubMed Central  Google Scholar 

Qin J, Luo M, Qian H, Chen W. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1. Gene. 2014;538(2):342–7.

Article  CAS  PubMed  Google Scholar 

Yang Y, Fan H, Liu H, Lou X, Xiao N, Zhang C, et al. NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression. Cell Death Dis. 2024;15(7):506.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Yu S, Ma R, Deng L, Yi Y, Niu M, et al. Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of DeltaNp63alpha expression and promote breast cancer metastasis independent of HIF1alpha. Cell Death Differ. 2024;31(4):447–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15(1):18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Longley J, Johnson PWM. Epigenetics of indolent lymphoma and how it drives novel therapeutic approaches-focus on EZH2-targeted drugs. Curr Oncol Rep. 2021;23(7):76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Romero P, Richart L, Aflaki S, Petitalot A, Burton M, Michaud A, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. Nat Commun. 2024;15(1):3452.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tang Q, Leng S, Tan Y, Cheng H, Liu Q, Wang Z, et al. Chitosan/dextran-based organohydrogel delivers EZH2 inhibitor to epigenetically reprogram chemo/immuno-resistance in unresectable metastatic melanoma. Carbohydr Polym. 2024;346:122645.

Article  CAS  PubMed  Google Scholar 

Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, et al. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci. 2021;112(9):3627–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma H, Luo X, Zhou P, He N, Zhou J, Liu M, et al. USP21 promotes cell proliferation by maintaining the EZH2 level in diffuse large B-cell lymphoma. J Clin Lab Anal. 2021;35(3):e23693.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, et al. Mutant EZH2 Induces a pre-malignant lymphoma niche by reprogramming the immune response. Cancer Cell. 2020;37(5):655–73 e11.

Wang P, Xu L, Fan Y, Li B, Chen P, Zhang X, et al. EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16. Leuk Lymphoma. 2022;63(14):3370–7.

Article  CAS  PubMed  Google Scholar 

Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell. 2025;43(1):49–68 e9.

Zhou B, Liang X, Mei H, Qi S, Jiang Z, Wang A, et al. Discovery of IHMT-EZH2-115 as a potent and selective enhancer of Zeste Homolog 2 (EZH2) inhibitor for the treatment of B-cell lymphomas. J Med Chem. 2021;64(20):15170–88.

Article  CAS  PubMed  Google Scholar 

Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13(4):842–54.

Article  CAS  PubMed  Google Scholar 

Ito J, Yamagata K, Shinohara H, Shima Y, Katsumoto T, Aikawa Y, et al. Dual inhibition of EZH1/2 induces cell cycle arrest of B cell acute lymphoblastic leukemia cells through upregulation of CDKN1C and TP53INP1. Int J Hematol. 2023;117(1):78–89.

Article  CAS  PubMed  Google Scholar 

Li W, Bi C, Han Y, Tian T, Wang X, Bao H, et al. Targeting EZH1/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57(CDKN1C) and TP53INP1 in mantle cell lymphoma. Cancer Biol Med. 2019;16(3):530–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang D, Jin H, Zuo J, Kong Y, Zhang X, Dong Q, et al. Potential biomarkers screening to predict side effects of dexamethasone in different cancers. Mol Genet Genomic Med. 2020;8(4):e1160.

Article  PubMed  PubMed Central  Google Scholar